Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults

Frontiers in Immunology

Volumn 9, Issue FEB, 2018, Pages

  Eppensteiner, John ^a   Davis, Robert Patrick ^a   Barbas, Andrew S ^a   Kwun, Jean ^a   Lee, Jaewoo ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Damage associated molecular pattern; Extracellular vesicle; Inflammation; Polymer; Thrombosis; Transplantation; Trauma

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HISTONE; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; PROTEIN S 100;

ACCIDENT PREVENTION; ALLOTRANSPLANTATION; BLOOD CLOTTING; CANCER THERAPY; CELL MEMBRANE; EXOSOME; HUMAN; INJURY; INNATE IMMUNITY; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TRANSPLANTATION; TREATMENT FAILURE;

EID: 85041865377     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00190     Document Type: Review

References (187)

1. Haagsma JA, Graetz N, Bolliger I, Naghavi M, Higashi H, Mullany EC, et al. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Inj Prev (2016) 22(1):3-18. doi:10.1136/injuryprev-2015-041616
2. Moore K. Trauma mortality: understanding mortality distribution to improve outcomes. J Emerg Nurs (2014) 40(4):405-6. doi:10.1016/j.jen.2014.04.006
3. Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury (2009) 40(9):912-8. doi:10.1016/j.injury.2009.05.024
4. Perl M, Lomas-Neira J, Venet F, Chung CS, Ayala A. Pathogenesis of indirect (secondary) acute lung injury. Expert Rev Respir Med (2011) 5(1):115-26. doi:10.1586/ers.10.92
5. Feltracco P, Carollo C, Barbieri S, Pettenuzzo T, Ori C. Early respiratory complications after liver transplantation. World J Gastroenterol (2013) 19(48):9271-81. doi:10.3748/wjg.v19.i48.9271
6. Kawai T, Akira S. TLR signaling. Semin Immunol (2007) 19(1):24-32. doi:10.1016/j.smim.2006.12.004
7. Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol (2015) 6:422. doi:10.3389/fimmu.2015.00422
8. Pugin J. How tissue injury alarms the immune system and causes a systemic inflammatory response syndrome. Ann Intensive Care (2012) 2(1):27. doi:10.1186/2110-5820-2-27
9. Liaw PC, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev (2016) 30(4):257-61. doi:10.1016/j.blre.2015.12.004
10. Raymond SL, Holden DC, Mira JC, Stortz JA, Loftus TJ, Mohr AM, et al. Microbial recognition and danger signals in sepsis and trauma. Biochim Biophys Acta (2017) 1863(10 Pt B):2564-73. doi:10.1016/j.bbadis.2017.01.013
11. Zeytun A, Chaudhary A, Pardington P, Cary R, Gupta G. Induction of cytokines and chemokines by toll-like receptor signaling: strategies for control of inflammation. Crit Rev Immunol (2010) 30(1):53-67. doi:10.1615/CritRevImmunol.v30.i1.40
12. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 464(7285):104-7. doi:10.1038/nature08780
13. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature (2009) 458(7237):509-13. doi:10.1038/nature07710
14. Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem (2000) 46(3):319-23
15. Gould TJ, Vu TT, Stafford AR, Dwivedi DJ, Kim PY, Fox-Robichaud AE, et al. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. Arterioscler Thromb Vasc Biol (2015) 35(12):2544-53. doi:10.1161/ATVBAHA.115.306035
16. Bhagirath VC, Dwivedi DJ, Liaw PC. Comparison of the proinflammatory and procoagulant properties of nuclear, mitochondrial, and bacterial DNA. Shock (2015) 44(3):265-71. doi:10.1097/SHK.0000000000000397
17. Rahbar E, Cardenas JC, Baimukanova G, Usadi B, Bruhn R, Pati S, et al. Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients. J Transl Med (2015) 13:117. doi:10.1186/s12967-015-0481-5
18. Liu J, Pedersen LC. Anticoagulant heparan sulfate: structural specificity and biosynthesis. Appl Microbiol Biotechnol (2007) 74(2):263-72. doi:10.1007/s00253-006-0722-x
19. Goodall KJ, Poon IK, Phipps S, Hulett MD. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One (2014) 9(10):e109596. doi:10.1371/journal.pone.0109596
20. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med (2013) 187(2):160-9. doi:10.1164/rccm.201206-1037OC
21. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hagele H, Lichtnekert J, et al. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol (2012) 23(8):1375-88. doi:10.1681/ASN.2011111077
22. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock (2009) 32(1):17-22. doi:10.1097/SHK.0b013e3181997173
23. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost (2007) 5(1):109-16. doi:10.1111/j.1538-7836.2006.02255.x
24. Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2. J Biol Chem (2007) 282(25):18265-75. doi:10.1074/jbc.M606352200
25. Wang Y, Fang C, Gao H, Bilodeau ML, Zhang Z, Croce K, et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest (2014) 124(5):2160-71. doi:10.1172/JCI70966
26. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 97(7):889-901. doi:10.1016/S0092-8674(00)80801-6
27. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum (2005) 52(9):2936-46. doi:10.1002/art.21238
28. Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol (2014) 306(7):C621-33. doi:10.1152/ajpcell.00228.2013
29. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 29:139-62. doi:10.1146/annurev-immunol-030409-101323
30. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol (2014) 30:255-89. doi:10.1146/annurev-cellbio-101512-122326
31. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg (1973) 178(2):117-22. doi:10.1097/00000658-197308000-00001
32. Eiseman B, Beart R, Norton L. Multiple organ failure. Surg Gynecol Obstet (1977) 144(3):323-6
33. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest (1992) 101(6):1644-55. doi:10.1378/chest.101.6.1644
34. Deitch EA. Simple intestinal obstruction causes bacterial translocation in man. Arch Surg (1989) 124(6):699-701. doi:10.1001/archsurg.1989.01410060065013
35. Meakins JL. Etiology of multiple organ failure. J Trauma (1990) 30(12 Suppl):S165-8. doi:10.1097/00005373-199012001-00033
36. Regel G, Grotz M, Weltner T, Sturm JA, Tscherne H. Pattern of organ failure following severe trauma. World J Surg (1996) 20(4):422-9. doi:10.1007/s002689900067
37. Sauaia A, Moore EE, Johnson JL, Chin TL, Banerjee A, Sperry JL, et al. Temporal trends of postinjury multiple-organ failure: still resource intensive, morbid, and lethal. J Trauma Acute Care Surg (2014) 76(3):582-92. doi:10.1097/TA.0000000000000147
38. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med (1995) 23(10):1638-52. doi:10.1097/00003246-199510000-00007
39. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma (1996) 40(4):501-10. doi:10.1097/00005373-199604000-00001
40. Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, sequential organ failure assessment, and Marshall scoring systems. J Trauma Acute Care Surg (2017) 82(3):534-41. doi:10.1097/TA.0000000000001328
41. Kung C-T, Hsiao S-Y, Tsai T-C, Su C-M, Chang W-N, Huang C-R, et al. Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. J Transl Med (2012) 10:130. doi:10.1186/1479-5876-10-130
42. Itagaki K, Kaczmarek E, Lee YT, Tang IT, Isal B, Adibnia Y, et al. Mitochondrial DNA released by trauma induces neutrophil extracellular traps. PLoS One (2015) 10(3):e0120549. doi:10.1371/journal.pone.0120549
43. Cedervall J, Zhang Y, Olsson AK. Tumor-induced NETosis as a risk factor for metastasis and organ failure. Cancer Res (2016) 76(15):4311-5. doi:10.1158/0008-5472.CAN-15-3051
44. Lee KH, Kronbichler A, Park DD, Park Y, Moon H, Kim H, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev (2017) 16(11):1160-73. doi:10.1016/j.autrev.2017.09.012
45. Sandler N, Kaczmarek E, Itagaki K, Zheng Y, Otterbein L, Khabbaz K, et al. Mitochondrial DAMPs are released during cardiopulmonary bypass surgery and are associated with postoperative atrial fibrillation. Heart Lung Circ (2018) 27(1):122-9. doi:10.1016/j.hlc.2017.02.014
46. Zou J, Duffy B, Slade M, Young AL, Steward N, Hachem R, et al. Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. Hum Immunol (2017) 78(4):342-9. doi:10.1016/j.humimm.2017.03.002
47. Deane JA, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol (2006) 177(10):6573-8. doi:10.4049/jimmunol.177.10.6573
48. Saitoh S, Miyake K. Regulatory molecules required for nucleotide-sensing toll-like receptors. Immunol Rev (2009) 227(1):32-43. doi:10.1111/j.1600-065X.2008.00729.x
49. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol (2006) 7(1):49-56. doi:10.1038/ni1280
50. Prikhodko AS, Shabanov AK, Zinovkina LA, Popova EN, Aznauryan MA, Lanina NO, et al. Pure mitochondrial DNA does not activate human neutrophils in vitro. Biochemistry (Mosc) (2015) 80(5):629-35. doi:10.1134/S0006297915050168
51. Sipes JN, Suratt PM, Teates CD, Barada FA, Davis JS, Tegtmeyer CJ. A prospective study of plasma DNA in the diagnosis of pulmonary embolism. Am Rev Respir Dis (1978) 118(3):475-8. doi:10.1164/arrd.1978.118.3.475
52. Arnalich F, Maldifassi MC, Ciria E, Codoceo R, Renart J, Fernandez-Capitan C, et al. Plasma levels of mitochondrial and nuclear DNA in patients with massive pulmonary embolism in the emergency department: a prospective cohort study. Crit Care (2013) 17(3):R90. doi:10.1186/cc12735
53. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 107(36):15880-5. doi:10.1073/pnas.1005743107
54. Belgrano FS, de Abreu da Silva IC, Bastos de Oliveira FM, Fantappie MR, Mohana-Borges R. Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending. PLoS One (2013) 8(11):e79572. doi:10.1371/journal.pone.0079572
55. Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol (2015) 6:93. doi:10.3389/fphys.2015.00093
56. Stark K, Philippi V, Stockhausen S, Busse J, Antonelli A, Miller M, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood (2016) 128(20):2435-49. doi:10.1182/blood-2016-04-710632
57. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock (2006) 25(6):571-4. doi:10.1097/01.shk.0000209540.99176.72
58. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas (2006) 33(4):359-63. doi:10.1097/01.mpa.0000236741.15477.8b
59. Itoh T, Iwahashi S, Kanak MA, Shimoda M, Takita M, Chujo D, et al. Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes. Cell Transplant (2014) 23(2):153-65. doi:10.3727/096368912X658980
60. Volz HC, Laohachewin D, Schellberg D, Wienbrandt AR, Nelles M, Zugck C, et al. HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin Res Cardiol (2012) 101(6):427-35. doi:10.1007/s00392-011-0409-x
61. Li ZC, Cheng GQ, Hu KZ, Li MQ, Zang WP, Dong YQ, et al. Correlation of synovial fluid HMGB-1 levels with radiographic severity of knee osteoarthritis. Clin Invest Med (2011) 34(5):E298. doi:10.25011/cim.v34i5.15673
62. Ke X, Jin G, Yang Y, Cao X, Fang R, Feng X, et al. Synovial fluid HMGB-1 levels are associated with osteoarthritis severity. Clin Lab (2015) 61(7):809-18. doi:10.7754/Clin.Lab.2015.141205
63. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 107(26):11942-7. doi:10.1073/pnas.1003893107
64. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med (2010) 14(11):2592-603. doi:10.1111/j.1582-4934.2010.01127.x
65. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 18:250-9. doi:10.2119/molmed.2011.00389
66. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 209(9):1519-28. doi:10.1084/jem.20120189
67. Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest (2015) 125(12):4638-54. doi:10.1172/JCI81660
68. Yang X, Wang H, Zhang M, Liu J, Lv B, Chen F. HMGB1: a novel protein that induced platelets active and aggregation via toll-like receptor-4, NF-kappaB and cGMP dependent mechanisms. Diagn Pathol (2015) 10:134. doi:10.1186/s13000-015-0348-3
69. Ahrens I, Chen YC, Topcic D, Bode M, Haenel D, Hagemeyer CE, et al. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi. Thromb Haemost (2015) 114(5):994-1003. doi:10.1160/TH14-12-1073
70. Silk E, Zhao H, Weng H, Ma D. The role of extracellular histone in organ injury. Cell Death Dis (2017) 8(5):e2812. doi:10.1038/cddis.2017.52
71. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol (2011) 187(5):2626-31. doi:10.4049/jimmunol.1003930
72. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, et al. Endogenous histones function as alarmins in sterile inflammatory liver injury through toll-like receptor 9 in mice. Hepatology (2011) 54(3):999-1008. doi:10.1002/hep.24501
73. Noubouossie DF, Whelihan MF, Yu YB, Sparkenbaugh E, Pawlinski R, Monroe DM, et al. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood (2017) 129(8):1021-9. doi:10.1182/blood-2016-06-722298
74. Yang X, Li L, Liu J, Lv B, Chen F. Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-kappaB and AP-1. Thromb Res (2016) 137:211-8. doi:10.1016/j.thromres.2015.10.012
75. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood (2011) 118(13):3708-14. doi:10.1182/blood-2011-01-332676
76. Toh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med (2016) 36(6):505-12. doi:10.3343/alm.2016.36.6.505
77. Alhamdi Y, Abrams ST, Cheng Z, Jing S, Su D, Liu Z, et al. Circulating histones are major mediators of cardiac injury in patients with sepsis. Crit Care Med (2015) 43(10):2094-103. doi:10.1097/CCM.0000000000001162
78. Granowska M, Mather SJ, Jobling T, Naeem M, Burchell J, Taylor-Papadimitriou J, et al. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int J Biol Markers (1990) 5(2):89-96
79. Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2017) 14(1):43-64. doi:10.1038/cmi.2016.34
80. Rohde D, Schon C, Boerries M, Didrihsone I, Ritterhoff J, Kubatzky KF, et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via toll-like receptor 4. EMBO Mol Med (2014) 6(6):778-94. doi:10.15252/emmm.201303498
81. Chen B, Miller AL, Rebelatto M, Brewah Y, Rowe DC, Clarke L, et al. S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One (2015) 10(2):e0115828. doi:10.1371/journal.pone.0115828
82. Angelo MF, Aguirre A, Aviles Reyes RX, Villarreal A, Lukin J, Melendez M, et al. The proinflammatory RAGE/NF-kappaB pathway is involved in neuronal damage and reactive gliosis in a model of sleep apnea by intermittent hypoxia. PLoS One (2014) 9(9):e107901. doi:10.1371/journal.pone.0107901
83. Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, et al. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Invest (2017) 127(6):2133-47. doi:10.1172/JCI92450
84. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal (2010) 3(105):cm1. doi:10.1126/scisignal.3105cm1
85. Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine (2015) 75(2):280-90. doi:10.1016/j.cyto.2015.05.005
86. Scarpa M, Kessler S, Sadler T, West G, Homer C, McDonald C, et al. The epithelial danger signal IL-1alpha is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol (2015) 185(6):1624-37. doi:10.1016/j.ajpath.2015.02.018
87. Lugrin J, Parapanov R, Rosenblatt-Velin N, Rignault-Clerc S, Feihl F, Waeber B, et al. Cutting edge: IL-1alpha is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol (2015) 194(2):499-503. doi:10.4049/jimmunol.1401948
88. Di Paolo NC, Shayakhmetov DM. Interleukin 1alpha and the inflammatory process. Nat Immunol (2016) 17(8):906-13. doi:10.1038/ni.3503
89. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res (2012) 52(1-2):89-99. doi:10.1007/s12026-012-8283-9
90. Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol (2015) 308(7):L619-27. doi:10.1152/ajplung.00305.2014
91. Stojkovic S, Kaun C, Basilio J, Rauscher S, Hell L, Krychtiuk KA, et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep (2016) 6:25171. doi:10.1038/srep25171
92. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics (2017) 7(3):789-804. doi:10.7150/thno.18133
93. Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol (2009) 19(22):1875-85. doi:10.1016/j.cub.2009.09.059
94. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett (2009) 283(2):168-75. doi:10.1016/j.canlet.2009.03.041
95. Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci (2016) 17(2):171. doi:10.3390/ijms17020171
96. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles (2014) 3(1):24641. doi:10.3402/jev.v3.24641
97. Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood (2012) 119(3):756-66. doi:10.1182/blood-2011-02-338004
98. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med (1998) 4(5):594-600. doi:10.1038/nm0598-594
99. Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, et al. Donor dendritic cell-derived exosomes promote allograft-targeting immune response. J Clin Invest (2016) 126(8):2805-20. doi:10.1172/JCI84577
100. Marino J, Babiker-Mohamed MH, Crosby-Bertorini P, Paster JT, LeGuern C, Germana S, et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. Sci Immunol (2016) 1(1):aaf8759. doi:10.1126/sciimmunol.aaf8759
101. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res (2011) 17(5):959-64. doi:10.1158/1078-0432.CCR-10-1489
102. Rak J. Microparticles in cancer. Semin Thromb Hemost (2010) 36(8):888-906. doi:10.1055/s-0030-1267043
103. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 71(11):3792-801. doi:10.1158/0008-5472.CAN-10-4455
104. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia (2014) 28(4):970-3. doi:10.1038/leu.2014.41
105. Nassar W, El-Ansary M, Sabry D, Mostafa MA, Fayad T, Kotb E, et al. Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res (2016) 20:21. doi:10.1186/s40824-016-0068-0
106. Chang PY, Qu YQ, Wang J, Dong LH. The potential of mesenchymal stem cells in the management of radiation enteropathy. Cell Death Dis (2015) 6:e1840. doi:10.1038/cddis.2015.189
107. Muhsin-Sharafaldine MR, Saunderson SC, Dunn AC, Faed JM, Kleffmann T, McLellan AD. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget (2016) 7(35):56279-94. doi:10.18632/oncotarget.10783
108. Gardiner C, Harrison P, Belting M, Boing A, Campello E, Carter BS, et al. Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 educational day. J Extracell Vesicles (2015) 4:26901. doi:10.3402/jev.v4.26901
109. Souza AC, Yuen PS, Star RA. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int (2015) 87(6):1100-8. doi:10.1038/ki.2015.26
110. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury (2010) 41(1):21-6. doi:10.1016/j.injury.2009.07.010
111. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.iy.12.040194.005015
112. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 293(4):R1538-44. doi:10.1152/ajpregu.00272.2007
113. Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care (2009) 13(6):R174. doi:10.1186/cc8152
114. Wallin IE. A note on the morphology of bacteria symbiotic in the tissues of higher organisms. J Bacteriol (1922) 7(5):471-4
115. Liu B, Du Q, Chen L, Fu G, Li S, Fu L, et al. CpG methylation patterns of human mitochondrial DNA. Sci Rep (2016) 6:23421. doi:10.1038/srep23421
116. Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock (2010) 34(1):55-9. doi:10.1097/SHK.0b013e3181cd8c08
117. Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol (2014) 6(5):a019133. doi:10.1101/cshperspect.a019133
118. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med (2013) 10(12):e1001577. doi:10.1371/journal.pmed.1001577
119. Simmons JD, Lee YL, Mulekar S, Kuck JL, Brevard SB, Gonzalez RP, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg (2013) 258(4):591-6. doi:10.1097/SLA.0b013e3182a4ea46
120. Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van Laarhoven A, et al. Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med (2016) 42(4):551-61. doi:10.1007/s00134-015-4205-3
121. Schiffmann E, Corcoran BA, Wahl SM. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A (1975) 72(3):1059-62. doi:10.1073/pnas.72.3.1059
122. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (2010) 330(6002):362-6. doi:10.1126/science.1195491
123. Braza F, Brouard S, Chadban S, Goldstein DR. Role of TLRs and DAMPs in allograft inflammation and transplant outcomes. Nat Rev Nephrol (2016) 12(5):281-90. doi:10.1038/nrneph.2016.41
124. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and damage-associated molecular patterns (DAMPs). Am J Transplant (2016) 16(12):3338-61. doi:10.1111/ajt.13963
125. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 16(8):943-9. doi:10.1002/lt.22091
126. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 104(15):6388-93. doi:10.1073/pnas.0608647104
127. Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A (2012) 109(32):12938-43. doi:10.1073/pnas.1204928109
128. Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. DAMP-induced allograft and tumor rejection: the circle is closing. Am J Transplant (2016) 16(12):3322-37. doi:10.1111/ajt.14012
129. Todd JL, Palmer SM. Danger signals in regulating the immune response to solid organ transplantation. J Clin Invest (2017) 127(7):2464-72. doi:10.1172/JCI90594
130. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 160(6):809-15. doi:10.1001/archinte.160.6.809
131. Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichle S, Mourey G, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol (2014) 134(1):176-82. doi:10.1038/jid.2013.288
132. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost (2015) 13(7):1310-9. doi:10.1111/jth.13002
133. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2007) 5(3):520-7. doi:10.1111/j.1538-7836.2007.02369.x
134. Sartori MT, Della Puppa A, Ballin A, Saggiorato G, Bernardi D, Padoan A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol (2011) 104(1):225-31. doi:10.1007/s11060-010-0462-8
135. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. J Clin Oncol (2017) 35(10):1078-85. doi:10.1200/JCO.2016.67.4564
136. Boles JC, Williams JC, Hollingsworth RM, Wang JG, Glover SL, Owens AP III, et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res (2012) 129(2):197-203. doi:10.1016/j.thromres.2011.06.022
137. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost (2007) 5(12):2445-52. doi:10.1111/j.1538-7836.2007.02788.x
138. Fu Y, Zhou J, Li H, Cao F, Su Y, Fan S, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost (2010) 104(6):1235-41. doi:10.1160/TH10-02-0102
139. Zhou J, Zheng Y, Shi J, Lu C, Hou J, Yu H, et al. Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells. Thromb Res (2010) 125(2):178-83. doi:10.1016/j.thromres.2009.09.006
140. Goldin-Lang P, Niebergall F, Antoniak S, Szotowski B, Rosenthal P, Pels K, et al. Ionizing radiation induces upregulation of cellular procoagulability and tissue factor expression in human peripheral blood mononuclear cells. Thromb Res (2007) 120(6):857-64. doi:10.1016/j.thromres.2007.01.008
141. Lysov Z, Swystun LL, Kuruvilla S, Arnold A, Liaw PC. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagul Fibrinolysis (2015) 26(1):36-45. doi:10.1097/MBC.0000000000000145
142. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13(9):1050-9. doi:10.1038/nm1622
143. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 202(12):1691-701. doi:10.1084/jem.20050915
144. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res (2011) 71(7):2488-96. doi:10.1158/0008-5472.CAN-10-2820
145. Duewell P, Beller E, Kirchleitner SV, Adunka T, Bourhis H, Siveke J, et al. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. Oncoimmunology (2015) 4(10):e1029698. doi:10.1080/2162402X.2015.1029698
146. Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ (2014) 21(12):1825-37. doi:10.1038/cdd.2014.96
147. De Munck J, Binks A, McNeish IA, Aerts JL. Oncolytic virus-induced cell death and immunity: a match made in heaven? J Leukoc Biol (2017) 102(3):631-43. doi:10.1189/jlb.5RU0117-040R
148. Bandyopadhyay S, Quinn TJ, Scandiuzzi L, Basu I, Partanen A, Tome WA, et al. Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape. J Immunol (2016) 196(4):1964-76. doi:10.4049/jimmunol.1500541
149. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 6(7):722-9. doi:10.1038/ni1213
150. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 208(10):1989-2003. doi:10.1084/jem.20101158
151. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+ dendritic cells. J Exp Med (2011) 208(10):2005-16. doi:10.1084/jem.20101159
152. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 12(12):860-75. doi:10.1038/nrc3380
153. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 461(7261):282-6. doi:10.1038/nature08296
154. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 123(2):321-34. doi:10.1016/j.cell.2005.08.032
155. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol (2013) 31:51-72. doi:10.1146/annurev-immunol-032712-100008
156. McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol (2012) 5:75. doi:10.1186/1756-8722-5-75
157. Sammon JD, Klett DE, Sood A, Olugbade K Jr, Schmid M, Kim SP, et al. Sepsis after major cancer surgery. J Surg Res (2015) 193(2):788-94. doi:10.1016/j.jss.2014.07.046
158. Taira F, Horimoto Y, Saito M. Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature. Breast Cancer (2015) 22(6):664-8. doi:10.1007/s12282-013-0448-4
159. Macaluso A, Genova S, Maringhini S, Coffaro G, Ziino O, D'Angelo P. Acute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia. Pediatr Rep (2015) 7(1):5760. doi:10.4081/pr.2015.5760
160. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature (2013) 497(7450):498-502. doi:10.1038/nature12118
161. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 309(11):1154-62. doi:10.1001/jama.2013.2194
162. Neal MD, Jia H, Eyer B, Good M, Guerriero CJ, Sodhi CP, et al. Discovery and validation of a new class of small molecule toll-like receptor 4 (TLR4) inhibitors. PLoS One (2013) 8(6):e65779. doi:10.1371/journal.pone.0065779
163. Sodhi CP, Jia H, Yamaguchi Y, Lu P, Good M, Egan C, et al. Intestinal epithelial TLR-4 Activation Is required for the development of acute lung injury after trauma/hemorrhagic shock via the release of HMGB1 from the gut. J Immunol (2015) 194(10):4931-9. doi:10.4049/jimmunol.1402490
164. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 38(8):1685-94. doi:10.1097/CCM.0b013e3181e7c5c9
165. Chen C, Wang Y, Zhang Z, Wang C, Peng M. Toll-like receptor 4 regulates heme oxygenase-1 expression after hemorrhagic shock induced acute lung injury in mice: requirement of p38 mitogen-activated protein kinase activation. Shock (2009) 31(5):486-92. doi:10.1097/SHK.0b013e318188f7e1
166. Ballard-Croft C, White DJ, Maass DL, Hybki DP, Horton JW. Role of p38 mitogen-activated protein kinase in cardiac myocyte secretion of the inflammatory cytokine TNF-alpha. Am J Physiol Heart Circ Physiol (2001) 280(5):H1970-81. doi:10.1152/ajpheart.2001.280.5.H1970
167. Su J, Cui X, Li Y, Mani H, Ferreyra GA, Danner RL, et al. SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice. J Trauma (2010) 68(6):1317-27. doi:10.1097/TA.0b013e3181bb9cd3
168. Lima CX, Souza DG, Amaral FA, Fagundes CT, Rodrigues IP, Alves-Filho JC, et al. Therapeutic effects of treatment with anti-TLR2 and anti-TLR4 monoclonal antibodies in polymicrobial sepsis. PLoS One (2015) 10(7):e0132336. doi:10.1371/journal.pone.0132336
169. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med (2008) 205(11):2609-21. doi:10.1084/jem.20081370
170. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, et al. Treatment with OPN-305, a humanized anti-toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv (2012) 5(2):279-87. doi:10.1161/CIRCINTERVENTIONS.111.967596
171. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Natl Acad Sci U S A (2003) 100(11):6646-51. doi:10.1073/pnas.0631696100
172. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, et al. Chloroquine and inhibition of toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 294(5):F1050-8. doi:10.1152/ajprenal.00461.2007
173. Fang H, Liu A, Dahmen U, Dirsch O. Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase. Cell Death Dis (2013) 4:e694. doi:10.1038/cddis.2013.225
174. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 1(1):e29911. doi:10.4161/mco.29911
175. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother (2015) 70(6):1608-21. doi:10.1093/jac/dkv018
176. Plitas G, Burt BM, Nguyen HM, Bamboat ZM, DeMatteo RP. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med (2008) 205(6):1277-83. doi:10.1084/jem.20080162
177. Yanai H, Chiba S, Ban T, Nakaima Y, Onoe T, Honda K, et al. Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc Natl Acad Sci U S A (2011) 108(28):11542-7. doi:10.1073/pnas.1108535108
178. Huang H, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, et al. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology (2015) 62(2):600-14. doi:10.1002/hep.27841
179. Simmons JD, Freno DR, Muscat CA, Obiako B, Lee YL, Pastukh VM, et al. Mitochondrial DNA damage associated molecular patterns in ventilator-associated pneumonia: prevention and reversal by intratracheal DNase I. J Trauma Acute Care Surg (2017) 82(1):120-5. doi:10.1097/TA.0000000000001269
180. Azevedo LC, Janiszewski M, Pontieri V, Pedro Mde A, Bassi E, Tucci PJ, et al. Platelet-derived exosomes from septic shock patients induce myocardial dysfunction. Crit Care (2007) 11(6):R120. doi:10.1186/cc6176
181. Janiszewski M, Do Carmo AO, Pedro MA, Silva E, Knobel E, Laurindo FR. Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway. Crit Care Med (2004) 32(3):818-25. doi:10.1097/01.CCM.0000114829.17746.19
182. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science (2008) 319(5867):1244-7. doi:10.1126/science.1153124
183. Essandoh K, Yang L, Wang X, Huang W, Qin D, Hao J, et al. Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochim Biophys Acta (2015) 1852(11):2362-71. doi:10.1016/j.bbadis.2015.08.010
184. Merkle HP. Drug delivery's quest for polymers: where are the frontiers? Eur J Pharm Biopharm (2015) 97(Pt B):293-303. doi:10.1016/j.ejpb.2015.04.038
185. Wagner E. Polymers for nucleic acid transfer-an overview. Adv Genet (2014) 88:231-61. doi:10.1016/B978-0-12-800148-6.00008-0
186. Lee J, Sohn JW, Zhang Y, Leong KW, Pisetsky D, Sullenger BA. Nucleic acid-binding polymers as anti-inflammatory agents. Proc Natl Acad Sci U S A (2011) 108(34):14055-60. doi:10.1073/pnas.1105777108
187. Lee J, Jackman JG, Kwun J, Manook M, Moreno A, Elster EA, et al. Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials (2017) 120:94-102. doi:10.1016/j.biomaterials.2016.12.024